Login to Your Account



CAT Restructures Amgen Deal, Pays Less Development Costs

By Nuala Moran


Wednesday, December 31, 2003
LONDON - Cambridge Antibody Technology Group plc is axing the 50 percent contribution it makes to its antibody development and marketing agreement with Amgen Inc. in favor of a deal in which Amgen meets all the costs and, rather than getting a 50 percent share of the profits, CAT receives fees, milestones and royalties. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription